CryoCath Technologies

CryoCath Technologies is a pioneering medical device company that specialized in the development of cryotherapy products for the treatment of cardiac arrhythmias, particularly atrial fibrillation. The company's flagship technology, the Arctic Front cryoballoon catheter, revolutionized the field by using cold energy to create circumferential lesions around the pulmonary veins, effectively blocking the irregular electrical signals that cause arrhythmias. Founded in 1995 and based in Montreal, CryoCath established itself as a leader in minimally invasive electrophysiology before its acquisition by Medtronic in 2008. Its cryoablation platform offered a safer and more efficient alternative to traditional radiofrequency heat-based ablation. Today, the technology developed by CryoCath remains a cornerstone of Medtronic's cardiac ablation portfolio and is a standard of care globally.